Login / Signup

CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa ® assays targeting distinct amyloid regions.

Anna Lidia WojdaƚaGiovanni BellomoAndrea TojaLorenzo GaetaniLucilla ParnettiDavide Chiasserini
Published in: Clinical chemistry and laboratory medicine (2023)
While both Aβ42/40 assays allowed for an effective discrimination between CTRL and different AD stages, the assay targeting amyloid N-terminal region provided the best diagnostic performance in plasma. Differences observed in technical and diagnostic performance of the two assays may depend on matrix-specific amyloid processing, suggesting that further studies should be carried to standardize amyloid ratio measurement in plasma.
Keyphrases
  • high throughput
  • cancer therapy
  • gold nanoparticles
  • mass spectrometry
  • drug delivery